M. ARTAC Et Al. , "The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.," Journal of cancer research and clinical oncology , vol.136, pp.803-9, 2010
ARTAC, M. Et Al. 2010. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.. Journal of cancer research and clinical oncology , vol.136 , 803-9.
ARTAC, M., BOZCUK, H., Pehlivan, S., AKCAN, S., PEHLIVAN, M., SEVER, T., ... OZDOGAN, M.(2010). The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.. Journal of cancer research and clinical oncology , vol.136, 803-9.
ARTAC, M Et Al. "The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.," Journal of cancer research and clinical oncology , vol.136, 803-9, 2010
ARTAC, M Et Al. "The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.." Journal of cancer research and clinical oncology , vol.136, pp.803-9, 2010
ARTAC, M. Et Al. (2010) . "The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.." Journal of cancer research and clinical oncology , vol.136, pp.803-9.
@article{article, author={M ARTAC Et Al. }, title={The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.}, journal={Journal of cancer research and clinical oncology}, year=2010, pages={803-9} }